A Partnership Deal or Buyout for Imugene?, page-76

Not to be confused with anything Imugene is working on. The article posted relates to Car-T therapy.

From IMUs website, there is explanation of the difference......


B-cell cancer vaccines are distinct from T-cell cancer vaccines, which bind to class I MHC molecules on antigen-presenting cells and are recognised by cytotoxic T-cells. Although several T-cell vaccines have shown limited therapeutic benefits in clinical trials, they have not caused striking tumour regression

B-cell immunotherapies link an immunogenic protein with a B-cell epitope and incorporate an adjuvant to produce a B-cell cancer vaccine that induces the body to produce antibodies against the normal self-proteins, such as HER2 or PD-1 (known as breaking immune tolerance). The antibodies produced following the vaccination are a ‘polyclonal’ mixture of antibodies that bind to different parts of the vaccine antigen. This makes them somewhat different to the monoclonal antibody drugs, even though they bind to the same target in the body.The use of B-cell immunotherapies to stimulate the patient’s immune system to produce polyclonal antibodies may have advantages over synthetic antibodies, including:Lower cost of production: B-cell immunotherapies are much cheaper to manufacture than mAb drugs.The polyclonal antibody response may reduce the risk of the tumour becoming resistant to the therapy and could potentially improve efficacy.The vaccine stimulates continuous antibody production via a lasting immune response that may inhibit tumour recurrence.

Although IMU doesn’t work on this type of therapy, CHM does involving some of IMU’s star talent.

PDS